
Anne L. Holleran
Examiner (ID: 1384, Phone: (571)272-0833 , Office: P/1642 )
| Most Active Art Unit | 1642 |
| Art Unit(s) | 1643, 1642 |
| Total Applications | 775 |
| Issued Applications | 297 |
| Pending Applications | 125 |
| Abandoned Applications | 356 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 9413337
[patent_doc_number] => 08697373
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-04-15
[patent_title] => 'Reagents and methods for use in cancer diagnosis, classification and therapy'
[patent_app_type] => utility
[patent_app_number] => 12/444007
[patent_app_country] => US
[patent_app_date] => 2007-10-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 4
[patent_no_of_words] => 17157
[patent_no_of_claims] => 15
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12444007
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/444007 | Reagents and methods for use in cancer diagnosis, classification and therapy | Oct 8, 2007 | Issued |
Array
(
[id] => 11276046
[patent_doc_number] => 09492518
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2016-11-15
[patent_title] => 'Tumor immunity'
[patent_app_type] => utility
[patent_app_number] => 12/444047
[patent_app_country] => US
[patent_app_date] => 2007-10-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 21515
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 99
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12444047
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/444047 | Tumor immunity | Oct 3, 2007 | Issued |
Array
(
[id] => 4872721
[patent_doc_number] => 20080199455
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-08-21
[patent_title] => 'Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same'
[patent_app_type] => utility
[patent_app_number] => 11/906968
[patent_app_country] => US
[patent_app_date] => 2007-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 13
[patent_no_of_words] => 11715
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0199/20080199455.pdf
[firstpage_image] =>[orig_patent_app_number] => 11906968
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/906968 | Conformation specific antibodies that bind trefoil factors and methods of treating cancers and proliferation disorders using same | Oct 2, 2007 | Abandoned |
Array
(
[id] => 5532944
[patent_doc_number] => 20090232732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-09-17
[patent_title] => 'PRO108 Antibody Compositions and Methods of Use and Use of PRO108 to Assess Cancer Risk'
[patent_app_type] => utility
[patent_app_number] => 11/866475
[patent_app_country] => US
[patent_app_date] => 2007-10-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 50320
[patent_no_of_claims] => 64
[patent_no_of_ind_claims] => 15
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0232/20090232732.pdf
[firstpage_image] =>[orig_patent_app_number] => 11866475
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/866475 | Pro108 antibody compositions and methods of use and use of Pro108 to assess cancer risk | Oct 2, 2007 | Issued |
Array
(
[id] => 4718639
[patent_doc_number] => 20080241161
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-10-02
[patent_title] => 'REMEDY FOR MAMMARY CANCER'
[patent_app_type] => utility
[patent_app_number] => 11/863679
[patent_app_country] => US
[patent_app_date] => 2007-09-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 5097
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0241/20080241161.pdf
[firstpage_image] =>[orig_patent_app_number] => 11863679
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/863679 | REMEDY FOR MAMMARY CANCER | Sep 27, 2007 | Abandoned |
| 10/587051 | M-Csf Muteins and Uses Thereof | Sep 3, 2007 | Abandoned |
Array
(
[id] => 5272472
[patent_doc_number] => 20090076248
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-03-19
[patent_title] => 'Plus end-directed microtubule motor required for chromosome congression'
[patent_app_type] => utility
[patent_app_number] => 11/895288
[patent_app_country] => US
[patent_app_date] => 2007-08-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 5
[patent_no_of_words] => 21272
[patent_no_of_claims] => 33
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0076/20090076248.pdf
[firstpage_image] =>[orig_patent_app_number] => 11895288
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/895288 | Plus end-directed microtubule motor required for chromosome congression | Aug 21, 2007 | Abandoned |
Array
(
[id] => 6220018
[patent_doc_number] => 20100055113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-03-04
[patent_title] => 'CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR'
[patent_app_type] => utility
[patent_app_number] => 12/374787
[patent_app_country] => US
[patent_app_date] => 2007-07-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 30934
[patent_no_of_claims] => 32
[patent_no_of_ind_claims] => 20
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0055/20100055113.pdf
[firstpage_image] =>[orig_patent_app_number] => 12374787
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/374787 | CELLULAR RECEPTOR FOR ANTIPROLIFERATIVE FACTOR | Jul 26, 2007 | Abandoned |
Array
(
[id] => 5230312
[patent_doc_number] => 20070292419
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2007-12-20
[patent_title] => 'TREATMENT WITH ANTI-ERBB2 ANTIBODIES'
[patent_app_type] => utility
[patent_app_number] => 11/780640
[patent_app_country] => US
[patent_app_date] => 2007-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 17532
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0292/20070292419.pdf
[firstpage_image] =>[orig_patent_app_number] => 11780640
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/780640 | Treatment with anti-ErbB2 antibodies | Jul 19, 2007 | Issued |
Array
(
[id] => 4718603
[patent_doc_number] => 20080241125
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-10-02
[patent_title] => 'MUC1-IKB KINASE COMPLEXES AND THEIR ACTIVITIES'
[patent_app_type] => utility
[patent_app_number] => 11/781148
[patent_app_country] => US
[patent_app_date] => 2007-07-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 33038
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0241/20080241125.pdf
[firstpage_image] =>[orig_patent_app_number] => 11781148
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/781148 | MUC1-IκB kinase complexes and their activities | Jul 19, 2007 | Issued |
Array
(
[id] => 4752561
[patent_doc_number] => 20080160636
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-07-03
[patent_title] => 'Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same'
[patent_app_type] => utility
[patent_app_number] => 11/821459
[patent_app_country] => US
[patent_app_date] => 2007-06-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 50429
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0160/20080160636.pdf
[firstpage_image] =>[orig_patent_app_number] => 11821459
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/821459 | Isolated GRP94 ligand binding domain polypeptide and nucleic acid encoding same, and screening methods employing same | Jun 21, 2007 | Abandoned |
Array
(
[id] => 177532
[patent_doc_number] => 07655239
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2010-02-02
[patent_title] => 'Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated'
[patent_app_type] => utility
[patent_app_number] => 11/821574
[patent_app_country] => US
[patent_app_date] => 2007-06-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 20
[patent_figures_cnt] => 29
[patent_no_of_words] => 17882
[patent_no_of_claims] => 8
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 105
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/655/07655239.pdf
[firstpage_image] =>[orig_patent_app_number] => 11821574
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/821574 | Immune reactivity to HER-2/neu protein for diagnosis and treatment of malignancies in which the HER-2/neu oncogene is associated | Jun 20, 2007 | Issued |
Array
(
[id] => 5446062
[patent_doc_number] => 20090047288
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2009-02-19
[patent_title] => 'Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity'
[patent_app_type] => utility
[patent_app_number] => 11/818697
[patent_app_country] => US
[patent_app_date] => 2007-06-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 10
[patent_no_of_words] => 11632
[patent_no_of_claims] => 6
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0047/20090047288.pdf
[firstpage_image] =>[orig_patent_app_number] => 11818697
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/818697 | Glucan compositions and methods of enhancing CR3 dependent neutrophil-mediated cytotoxicity | Jun 14, 2007 | Abandoned |
Array
(
[id] => 4687700
[patent_doc_number] => 20080031881
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-02-07
[patent_title] => 'MEDICAMENT FOR TREATING CANCER'
[patent_app_type] => utility
[patent_app_number] => 11/761264
[patent_app_country] => US
[patent_app_date] => 2007-06-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 5058
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0031/20080031881.pdf
[firstpage_image] =>[orig_patent_app_number] => 11761264
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/761264 | Medicament for treating cancer | Jun 10, 2007 | Issued |
Array
(
[id] => 5959029
[patent_doc_number] => 20110183416
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2011-07-28
[patent_title] => 'Method of modulating the proliferation of medullary thyroid carcinoma cells'
[patent_app_type] => utility
[patent_app_number] => 11/810268
[patent_app_country] => US
[patent_app_date] => 2007-06-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 7
[patent_no_of_words] => 8575
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0183/20110183416.pdf
[firstpage_image] =>[orig_patent_app_number] => 11810268
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/810268 | Method of modulating the proliferation of medullary thyroid carcinoma cells | Jun 4, 2007 | Abandoned |
Array
(
[id] => 4455294
[patent_doc_number] => 07892554
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2011-02-22
[patent_title] => 'Internalizing ErbB2 antibodies'
[patent_app_type] => utility
[patent_app_number] => 11/809773
[patent_app_country] => US
[patent_app_date] => 2007-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 2
[patent_figures_cnt] => 2
[patent_no_of_words] => 28698
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 98
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] => patents/07/892/07892554.pdf
[firstpage_image] =>[orig_patent_app_number] => 11809773
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/809773 | Internalizing ErbB2 antibodies | May 31, 2007 | Issued |
Array
(
[id] => 8920481
[patent_doc_number] => 08486412
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2013-07-16
[patent_title] => 'Immunity to folate receptors'
[patent_app_type] => utility
[patent_app_number] => 12/303054
[patent_app_country] => US
[patent_app_date] => 2007-06-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 4
[patent_figures_cnt] => 6
[patent_no_of_words] => 9973
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 54
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 12303054
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/303054 | Immunity to folate receptors | May 31, 2007 | Issued |
Array
(
[id] => 6493492
[patent_doc_number] => 20100209426
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2010-08-19
[patent_title] => 'INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE'
[patent_app_type] => utility
[patent_app_number] => 12/301661
[patent_app_country] => US
[patent_app_date] => 2007-05-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 18
[patent_no_of_words] => 19053
[patent_no_of_claims] => 22
[patent_no_of_ind_claims] => 7
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0209/20100209426.pdf
[firstpage_image] =>[orig_patent_app_number] => 12301661
[rel_patent_id] =>[rel_patent_doc_number] =>) 12/301661 | INHIBITORS OF PROGASTRIN-INDUCED REPRESSION OF ICAT FOR TREATING AND/OR PREVENTING COLORECTAL CANCER, ADENOMATOUS POLYPOSIS OR METASTASIS DISPLAYING PROGASTRIN-SECRETING CELLS AND CELLS IN WHICH THE BETA-CATENIN/TCF-MEDIATED TRANSCRIPTIONAL PATHWAY IS CONSTITUTIVELY ACTIVE | May 20, 2007 | Abandoned |
Array
(
[id] => 4797120
[patent_doc_number] => 20080008706
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2008-01-10
[patent_title] => 'B7S1: an immune modulator'
[patent_app_type] => utility
[patent_app_number] => 11/804398
[patent_app_country] => US
[patent_app_date] => 2007-05-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 8
[patent_figures_cnt] => 8
[patent_no_of_words] => 21750
[patent_no_of_claims] => 13
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 0
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] => publications/A1/0008/20080008706.pdf
[firstpage_image] =>[orig_patent_app_number] => 11804398
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/804398 | B7S1: an immune modulator | May 16, 2007 | Abandoned |
Array
(
[id] => 9375792
[patent_doc_number] => 08680056
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2014-03-25
[patent_title] => 'Antiproliferative factor and methods of use'
[patent_app_type] => utility
[patent_app_number] => 11/743865
[patent_app_country] => US
[patent_app_date] => 2007-05-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 10
[patent_no_of_words] => 25032
[patent_no_of_claims] => 5
[patent_no_of_ind_claims] => 5
[patent_words_short_claim] => 51
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 11743865
[rel_patent_id] =>[rel_patent_doc_number] =>) 11/743865 | Antiproliferative factor and methods of use | May 2, 2007 | Issued |